Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / RIGL - Akoya Biosciences Announces that Garry Nolan Ph.D. James Allison Ph.D. and Padmanee Sharma M.D. Ph.D. Join Newly Created Scientific Advisory Board | Benzinga


RIGL - Akoya Biosciences Announces that Garry Nolan Ph.D. James Allison Ph.D. and Padmanee Sharma M.D. Ph.D. Join Newly Created Scientific Advisory Board | Benzinga

  • MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the establishment of its Scientific Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial biology solutions for the life sciences industry, from discovery to diagnostics.

    The initial members of Akoya's Scientific Advisory Board are:

    • Garry Nolan, Ph.D., Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine, co-founder of Akoya Biosciences and inventor of the CODEX technology (now PhenoCycler)
    • James Allison, Ph.D., Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, and Director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center; recipient of the 2018 Nobel Prize in Physiology or Medicine
    • Padmanee Sharma, M.D., Ph.D., Professor in the Departments of Genitourinary Medical Oncology and Immunology, Associate VP of Immunobiology, the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology, and Director of Scientific Programs for the James P. Allison Institute at MD Anderson

    "Our SAB includes leaders in immunotherapy, immunobiology and innovation with deep knowledge and experience in translational research, the discovery of ground-breaking clinical therapies and the development of disruptive and high impact technologies," said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. "By bringing together experts with unparalleled track records of success, the SAB will enable us to better serve customer needs, accelerate our leadership position in spatial biology, and support Akoya's mission to catalyze discovery and improve patient care."

    Garry Nolan, Ph.D.

    Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB. He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. As a co-inventor of the CODEX technology, Garry has focused his research efforts on developing novel technologies and computational methods for research into cancer, leukemia, immunology, and autoimmune disease. Professor Nolan was the founder of a number of life sciences companies in addition to Akoya, including Rigel Inc. (NASDAQ:RIGL), DVS Sciences (purchased by Fluidigm), Nodality, Inc., BINA (sold to Roche Diagnostics), Apprise (sold to Roche Sequencing Solutions), Scale Bio (single cell ATAC, RNA, and protein), and serves as an advisor and board member for several biotechnology companies. He has published over ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Rigel Pharmaceuticals Inc.
    Stock Symbol: RIGL
    Market: NASDAQ
    Website: rigel.com

    Menu

    RIGL RIGL Quote RIGL Short RIGL News RIGL Articles RIGL Message Board
    Get RIGL Alerts

    News, Short Squeeze, Breakout and More Instantly...